OpenEvidence vs Exa
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
Exa
Web search and retrieval API built for AI agents and apps
Visit
|
|
|---|---|---|
| RECATOOLS Score | 7.8 / 10 | 7.7 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Freemium | Freemium |
| Free tier | Free for all verified US clinicians (NPI required); ad-supported | 20,000 search requests per month on the free plan; startup and education grants of $1,000 in free API credits also available |
| Paid from | Enterprise tier in development; pricing undisclosed — contact sales | API search billed at $7 per 1,000 requests (as of March 2026 pricing update) |
| Has API | ✗ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✓ | ✓ |
| Users | ~860,000 verified US clinicians (June 2026) | — |
| Founded | 2022 | 2021 |
| Maker | Daniel Nadler (CEO), Zachary Ziegler (CTO) | — |
| Verdict | OpenEvidence is genuinely transformative for US-based clinicians: it delivers fast, well-cited, evidence-grounded answers from top-tier journals at zero cost, making it arguably the strongest value proposition in medical... |
Exa is a credible, fast-moving entrant in the agent-search space, with a clean API, MCP support and strong investor backing as of 2026. It competes directly with Parallel and Tavily on freshness and structured retrieval... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.